NCT07225816 — "Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)" trial site landscape

Public-registry site landscape for NCT07225816, “Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)”, a Obesity study sponsored by Novo Nordisk A/S. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07225816 (registry record)
Study title	Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)
Official title	Investigation of the Effect of Fasting Duration and Temporary Withholding of GLP-1 RAs on Retained Gastric Contents in Participants Treated With s.c. Liraglutide, Oral Semaglutide or s.c. Semaglutide
Sponsor	Novo Nordisk A/S
Condition(s)	Obesity
Phase	PHASE1
Listed sites	1
Intervention(s)	Liraglutide, Oral Semaglutide, Semaglutide
Site countries	United States

Patient-friendly overview of this study: eichor.com/study/NCT07225816.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07225816 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →